Viatris (VTRS) Financials, Dividends & Stock Info
Explore comprehensive financial data for Viatris, provided completely free. Analyze revenue, net income, profit margins, dividend history, and key financial ratios to make informed investment decisions.
Data as of (572 days ago)|Source: SEC EDGAR
The information on this page is for informational purposes only and does not constitute investment advice, financial advice, or any recommendation. Billiver does not recommend buying, selling, or holding any security. Past performance is not indicative of future results.
Data may be delayed and accuracy is not guaranteed. All investment decisions are solely your responsibility. Verify information independently and consult a qualified financial advisor before investing. About · Methodology
Viatris (VTRS) is a pharmaceuticals company. The company reports annual revenue of $14.7B and net loss of $634M. Its profit margin is -4.3%.
Viatris Key Financials
Data from SEC EDGAR filings. TTM = Trailing Twelve Months.
Viatris Financial Health ScoreFY2025
Weak financial health; requires careful evaluation
-8 pts YoYThis Financial Health Score is a proprietary metric calculated from SEC EDGAR filings for educational and informational purposes only. It does not constitute investment advice or a recommendation to buy or sell any security. Results vary significantly by industry. Conduct your own research before making investment decisions.
Data Highlights
- Altman Z-Score 0.48 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Viatris Recent Events
Source: SEC EDGAR 8-K Filings
5-Year Revenue & Net Income Trend
Chart shows fiscal year data from SEC EDGAR filings. Hover over data points for details.
As of FY2025 · SEC 10-K · Updated Jun 30, 2026
Revenue Breakdown (FY2024)
See Viatris detailed breakdown →About Viatris
Viatris Inc. is an American global pharmaceutical and healthcare corporation headquartered in Canonsburg, Pennsylvania. The corporation was formed through the merger of Mylan and Upjohn, a legacy division of Pfizer, on November 16, 2020.
- Industry
- Pharmaceuticals
Valuation
Valuation Data UnavailablePrice-based valuation metrics (P/E, P/B) require real-time stock price data which is not included in SEC filings.
Benjamin Graham: Graham recommended P/E ratio not exceed 15 for reasonable valuation. Understanding valuation metrics
Profitability
Thin Marginsvs 7.2% sector median / 5.9% avg
Currently operating at a loss of 4 cents per dollar of revenue.
Profit margin 173% below sector average.
Warren Buffett: Buffett looks for consistent ROE above 20% as a sign of competitive advantage. How to evaluate profitability
Financial Health
Balance Sheet Data LimitedInsufficient data to assess financial health.
Peter Lynch: Lynch: normal balance sheet has 75% equity, 25% debt. Understanding financial health
Dividend
Dividend Data UnavailableDividend yield data is not available from SEC filings. Check the company's investor relations page for dividend information.
As of FY2025 · SEC 10-K · Updated Jun 30, 2026
Viatris 8-Year Revenue, Profit & Cash Flow History
Revenue has grown at a 3.2% CAGR over the past 7 years.
Annual Financials
FY2025 - FY2018| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $14.3B(-3.0%) | $14.7B(-4.5%) | $15.4B(+29.1%) | $11.9B(+3.9%) | $11.5B(+0.6%) | $11.4B(-0.6%) | $11.5B(+0.6%) | $11.4B |
| Net Income | $-3,514,900,000(-454.2%) | $-634,200,000(-1259.4%) | $54.7M(+108.2%) | $-669,900,000(-4087.5%) | $16.8M(-95.2%) | $352.5M | $0(-100.0%) | $352.5M |
| Total Assets | $37.2B | $41.5B | $47.7B | $50.0B | $54.8B | $61.6B | $31.3B | - |
| Total Debt | $12.5B | $14.0B | $16.2B | $18.0B | $19.7B | $22.4B | $11.2B | - |
| Total Equity | $14.7B | $18.6B | $20.5B | $23.0B | $11.9B | $12.2B | $0 | $12.2B |
| Profit Margin | -24.6% | -4.3% | 0.4% | -5.6% | 0.1% | 3.1% | - | 3.1% |
| ROE | -23.9% | -3.4% | 0.3% | -2.9% | 0.1% | 2.9% | - | 2.9% |
| ROA | -9.4% | -1.5% | 0.1% | -1.3% | 0.0% | 0.6% | - | - |
Quarterly Financials
Last 8 quarters| Metric | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.3B | $11.2B | $7.5B | $3.7B | $11.6B | $7.6B | $3.7B | $12.4B |
| Net Income | - | - | - | - | - | - | - | - |
| Total Assets | $37.2B | $41.5B | $41.5B | $41.5B | $47.7B | $47.7B | $47.7B | $50.0B |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026
Insider Trading
Source: SEC EDGAR Form 4 filings. Only purchase (P) and sale (S) transactions shown.
Viatris Dividend Safety Analysis & Growth History
Dividend Status
Dividend PayerThis company pays dividends. Historical dividend data shown below.
Annual Dividends
2021 - 2022| Metric | 2021 | 2022 |
|---|---|---|
| Dividend/Share | $0.22 | $0.24 |
| YoY Growth | - | +9.1% |
| Payments | 2 | 2 |
| Increased | - | Yes |
Learn more: Dividend investing guide | How to evaluate dividend safety
As of FY2025 · SEC 10-K · Updated Jun 30, 2026
Viatris Free Cash Flow & Dividend Coverage
Generates approximately $5M in free cash flow per day.
Cash Flow History
FY2018 - FY2025| Metric | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $2.3B | $1.8B | $2.3B | $1.8B | $1.2B | $2.9B | $2.3B | $2.3B |
| CapEx | -$252.1M | -$213.2M | -$252.1M | -$213.2M | -$243.0M | -$377.0M | -$326.0M | -$378.8M |
| Free Cash Flow | $2.1B | $1.6B | $2.1B | $1.6B | $988.8M | $2.5B | $2.0B | $1.9B |
| FCF Margin | 18.3% | 13.8% | 18.3% | 13.8% | 8.3% | 16.4% | 13.4% | 13.6% |
Source: SEC EDGAR 10-K filings. FCF = Operating Cash Flow - Capital Expenditures. Free cash flow guide
As of FY2025 · SEC 10-K · Updated Jun 30, 2026
Viatris Risk Factors
Company-disclosed SEC risk factors
Risk factors are disclosed by the company in its SEC Form 10-K, Item 1A. Billiver does not classify or summarize company-specific legal, operational, financial, or market risks here.
Sector context: Health Care. This is not a Billiver risk assessment for VTRS.
Source note: the SEC Form 10-K includes Item 1A, "Risk Factors." The full risk-factor text should be read from the company’s own SEC filing.
Viatris FAQ
What is Viatris's annual revenue?
Viatris (VTRS) reported $14.7 billion in trailing twelve-month (TTM) revenue. This financial data is compiled from SEC EDGAR 10-K filings.
Is Viatris profitable?
Viatris reported a net loss with a -4.3% profit margin, totaling $634 million in net losses (TTM). All figures from SEC EDGAR 10-K filings.
Does Viatris pay dividends?
Yes, Viatris pays regular dividends with 1 consecutive years of dividend payments. View the full dividend history and payout analysis on this page.
What is Viatris's financial health score?
Viatris has a financial health score of 49/100 (Grade: F), evaluating profitability, solvency, liquidity, and growth based on SEC EDGAR data.
How many years of Viatris financial data are available?
8 years of financial data are available for Viatris from FY2018 to FY2025. All figures are compiled from SEC EDGAR 10-K filings.